This review examined the effects of metformin on blood-pressure and lipid profile in type 2 diabetes. The authors concluded that metformin reduces total and low-density lipoprotein cholesterol slightly more than control treatments but has no effect on other outcomes. The review included a large number of trials and was reasonably well-conducted, and the authors' conclusions are likely to be reliable.
extraction. Data on trial characteristics, patient characteristics and primary outcomes were extracted. The authors of the identified studies were contacted for missing data. Where a study contained more than two treatment groups, data on monotherapy were used for the intervention and control groups. The control groups were prioritised as follows: placebo, insulin therapy, other treatments. Mean differences between the baseline and treatment data were calculated for each outcome measure where this was not reported in the primary study.
Methods of synthesis
How were the studies combined? The weighted mean differences (WMDs) between the baseline and treatment data were pooled in fixed-effect metaanalyses for each outcome measure. Publication bias was assessed using a funnel plot.
How were differences between studies investigated?
Statistical heterogeneity was assessed using chi-squared tests. A priori subgroup analyses were conducted on the basis of the dose of metformin employed. Where there was a significant difference between the groups, additional subgroup analyses were conducted: studies were divided into tertiles on the basis of difference in glycaemic control between metformin and the control group, body mass index, the duration of treatment follow-up and metformin dose; metformin administered as monotherapy or in conjunction with another antidiabetic treatment; and on the basis of the control treatment used. Analyses of the effect of methodological quality, year of publication and study design (parallel versus crossover) were also carried out.
Results of the review
Forty-one RCTs (n=3,074) were included in the review: 33 parallel trials and 8 crossover trials.
The authors reported that there was no evidence of publication bias, although this analysis was not shown. They also reported that there was no statistically significant heterogeneity between the studies; this was also not shown.
Systolic BP (21 trials, n=1,667): the pooled WMD showed no significant difference between the groups (WMD -1.09 mmHg, 95% confidence interval, CI: -3.01, 0.82). This was also the case in the trials using the highest doses of metformin (at least 2,550 mg/day): WMD 0.54 mmHg (95% CI: -1.94, 3.02).
Diastolic BP (19 trials, n=1,609): the pooled WMD showed no significant difference between the groups (WMD -0.97 mmHg, 95% CI: -2.15, 0.21). This was also the case in the trials using the highest doses of metformin (at least 2,550 mg/day): WMD -0.17 mmHg (95% CI: -1.62, 1.27).
HbA1c: there was a small but statistically significant increase in glycaemic control with metformin compared with the comparator (-0.74, 95% CI: -0.84, -0.65).
Plasma triglycerides (37 trials, n=2,891): the pooled WMD showed a significantly greater reduction in concentration of plasma triglycerides in the metformin groups than in the control groups (WMD -0.13 mmol/L, 95% CI: -0.21, -0.04). Sensitivity analyses showed that metformin significantly reduced triglycerides compared with control treatment only in the following: studies with the greatest difference in glycaemic control in favour of metformin; studies using the two highest range of doses of metformin; studies with intermediate length of follow-up; studies that compared metformin with insulin therapy; and studies in which metformin was administered as monotherapy.
Plasma total cholesterol (38 trials, n=2,973): the pooled WMD showed a significantly greater reduction in concentration of plasma total cholesterol in the metformin groups than in the control groups (WMD -0.26 mmol/L, 95% CI: -0.34, -0.18). Sensitivity analyses found no relationship between this effect and any of the variables investigated.
